Posted by Michael Wonder on 03 Dec 2020
FDA grant fast track designation for remestemcel-L in the treatment of acute respiratory distress syndrome due to COVID-19
2 December 2020 - Mesoblast today announced that the United States FDA has granted fast track designation for remestemcel-L in the treatment of acute respiratory distress syndrome (ARDS) due to COVID-19 infection.
ARDS is the primary cause of death in patients with COVID-19.
